Cancer-related inflammation: common themes and therapeutic opportunities.

By F. Balkwill, A. Mantovani. Seminars in Cancer Biology, 2012

669 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

From CRP to IL-6 to IL-1: Moving Upstream To Identify Novel Targets for Atheroprotection (2016, background): “Further, as canakinumab has been hypothesized to reduce metastatic disease in part through alteration of adhesion molecule function, incident cancers are also being tracked closely(101); this latter issue is collinear with interests in inhibition of IL-1 and innate immune function as a potential the”
CDK4/6 Inhibition Augments Anti-Tumor Immunity by Enhancing T Cell Activation (2017, background): “The digested NFATc3 and His-GB1 were separated and further purified using size exclusion chromatography (GE Healthcare Life Sciences “Superdex 75 10/300 GL”).”
Autophagy and autophagy-related proteins in cancer (2020, background): “In autophagy-defective cells and tissues, the failure to eliminate damaged proteins and organelles leads cellular dysfunction and death, and then stimulates an inflammation condition, and creates ultimately a cancer-prone environment [206].”
Tumor-associated macrophages: from mechanisms to therapy (2014, background): “Furthermore, inflammatory conditions such as Crohn’s disease dramatically increase the risk of colorectal cancer (Balkwill et al., 2005; Balkwill and Mantovani, 2012; Coussens and Werb, 2002; Grivennikov et al., 2010).”